Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  lonafarnib
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-15 of 15 for your search:
Start Over
Phase II Randomized Study of SCH 66336 vs Gemcitabine in Patients with Metastatic Adenocarcinoma of the Pancreas (Summary Last Modified 01/2000)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: CWRU-SCH-1298, SPRI-C98-545-18, NCI-G99-1534
Phase II Randomized Study of SCH 66336 Versus Gemcitabine in Patients With Metastatic Adenocarcinoma of the Pancreas (Summary Last Modified 01/2000)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: MSKCC-98115, SPRI-C98-545-12, NCI-G99-1571
Phase II Study of SCH 66336 in Patients With Metastatic Adenocarcinoma of the Pancreas Refractory to Gemcitabine (Summary Last Modified 03/2000)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: UCLA-9906030, SPRI-P00346, NCI-G99-1610
SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: EORTC-16997, EORTC-GU-16997, EORTC-PAMM-16997, NCT00006351
Phase II Randomized Study of Anastrozole With or Without Lonafarnib in Postmenopausal Women With Hormone Receptor-Positive Stage IIIB, IIIC or IV Breast Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: Postmenopausal
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: UCLA-0403073-01, SPRI-P03480, NCT00098904
Comparison of Paclitaxel/Carboplatin and Lonafarnib to Paclitaxel/Carboplatin for First-line Treatment of Ovarian Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: AGO-OVAR 15, NCT00281515
Phase I Study of Oral SCH 66336 in Patients with Solid Tumors (Summary Last Modified 04/2000)
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EORTC-16979, SPRI-I97-211
Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: EORTC-16023-10051, SPRI-P01900, NCT00068757
Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia
Phase: Phase I
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: Other
Protocol IDs: ID02-221, NCT00047502
Farnesyl Protein Transferase Inhibitor (FPTI) in Combination With Docetaxel in Advanced Solid Tumors (Study P01964)(COMPLETED)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 to 65
Sponsor: Pharmaceutical / Industry
Protocol IDs: P01964, NCT00040547
Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: Over 18
Sponsor: Other
Protocol IDs: EORTC-16027-26023, EORTC-16027, EORTC-26023, SPRI-P03174, NCT00083096
Sarasar and Temodar for Glioblastoma Multiforme Patients
Phase: Phase I
Type: Treatment
Status: Closed
Age: Over 18
Sponsor: Other
Protocol IDs: 2004-0424, SPRI # P04084, NCI-2012-01311, NCT00102648
PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: Pro00005027, 7009/Pro00005027, NCT00612651
SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors
Phase: Phase I
Type: Treatment
Status: Completed
Age: 21 and under
Sponsor: NCI, Other
Protocol IDs: CDR0000068571, PBTC-003, SPRI-P02201, NCT00015899
Start Over